476 related articles for article (PubMed ID: 16905375)
1. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
[TBL] [Abstract][Full Text] [Related]
2. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
3. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Grapsa EI; Passalidou IA; Tziamalis MP; Poulakou MV; Vlachos IS; Perrea DN
Hemodial Int; 2008 Jan; 12(1):100-7. PubMed ID: 18271850
[TBL] [Abstract][Full Text] [Related]
4. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
5. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
[TBL] [Abstract][Full Text] [Related]
6. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism.
Baek KH; Lee WY; Oh KW; Kim HS; Han JH; Kang MI; Cha BY; Lee KW; Son HY; Kang SK; Kim CC
J Clin Endocrinol Metab; 2004 Mar; 89(3):1246-54. PubMed ID: 15001618
[TBL] [Abstract][Full Text] [Related]
7. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
8. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Volin L; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Ruutu T
Bone Marrow Transplant; 1999 Feb; 23(4):355-61. PubMed ID: 10100579
[TBL] [Abstract][Full Text] [Related]
10. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
[TBL] [Abstract][Full Text] [Related]
11. Bone metabolism in patients more than five years after bone marrow transplantation.
Kerschan-Schindl K; Mitterbauer M; Füreder W; Kudlacek S; Grampp S; Bieglmayer C; Fialka-Moser V; Pietschmann P; Kalhs P
Bone Marrow Transplant; 2004 Sep; 34(6):491-6. PubMed ID: 15286695
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
13. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
14. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
[TBL] [Abstract][Full Text] [Related]
16. The role of cytokines in the changes in bone turnover following bone marrow transplantation.
Lee WY; Kang MI; Oh ES; Oh KW; Han JH; Cha BY; Lee KW; Son HY; Kang SK; Kim CC
Osteoporos Int; 2002 Jan; 13(1):62-8. PubMed ID: 11878457
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
18. Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation.
Lee WY; Baek KH; Rhee EJ; Tae HJ; Oh KW; Kang MI; Lee KW; Kim SW; Kim CC; Oh ES
Bone Marrow Transplant; 2004 Jul; 34(1):89-94. PubMed ID: 15170175
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
